$ News

Simulations Plus Announces Completion of Acquisition by Altaris

Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

Simulations Plus Announces The FDA Cosmetics Regulatory Science Branch Has Licensed ADMET Predictor To Support Its Computational Research For Modern Cosmetic Safety Assessment

Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris

Simulations Plus Clears HSR Waiting Period For Altaris Acquisition, Closing Expected In H2 2026

Simulations Plus, Inc. 2026 Q3 - Results - Earnings Call Presentation

Simulations Plus Affirms FY2026 Adj EPS Guidance of $0.75-$0.85 vs $0.42 Est; Affirms FY2026 Sales Guidance of $79.000M-$82.000M vs $81.598M Est

Simulations Plus (NASDAQ:SLP) Beats Q3 Estimates by Wide Margin but Shares Edge Lower on Profit-Taking

Simulations Plus Reports Third Quarter Fiscal 2026 Financial Results

Simulations Plus Q3 Adj. EPS $0.30 Beats $0.13 Estimate, Sales $21.886M Beat $20.918M Estimate

Sylvania Platinum (AIM:SLP) Stock Sees Modest Fair Value Lift As Analysts Weigh Cash Generation

Simulations Plus Announces Altaris To Pay $26M If Proposed Merger Plan Terminated

Altaris to acquire Simulations Plus in $375m all-cash deal

William Blair Downgrades Simulations Plus to Market Perform

Simulations Plus to Be Acquired by Altaris For Approximately $375 Million

Simulations Plus Agrees To Be Acquired By Altaris For $18.50/Share

Dividend Investors: Don't Be Too Quick To Buy SLP Resources Berhad (KLSE:SLP) For Its Upcoming Dividend

How The Investment Story Is Evolving For Sylvania Platinum (AIM:SLP)

Is It Too Late To Consider Buying Simulations Plus, Inc. (NASDAQ:SLP)?

Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference